Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of effect of mianserin on the symptoms of diabetic neuropathy.
Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Brøsen K, Beck-Nielsen H. Sindrup SH, et al. Among authors: tuxen c. Eur J Clin Pharmacol. 1992;43(3):251-5. doi: 10.1007/BF02333018. Eur J Clin Pharmacol. 1992. PMID: 1425887 Clinical Trial.
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Faber J, Malik ME, Fosbøl EL, Bruun NE, Forman JL, Jensen LT, Møller JE, Schou M. Jensen J, et al. Among authors: tuxen c. Lancet Diabetes Endocrinol. 2021 Feb;9(2):106-116. doi: 10.1016/S2213-8587(20)30382-X. Epub 2020 Dec 22. Lancet Diabetes Endocrinol. 2021. PMID: 33357505 Clinical Trial.
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
Omar M, Jensen J, Kistorp C, Højlund K, Videbæk L, Tuxen C, Larsen JH, Andersen CF, Gustafsson F, Køber L, Schou M, Møller JE. Omar M, et al. Among authors: tuxen c. Cardiovasc Diabetol. 2022 Feb 27;21(1):34. doi: 10.1186/s12933-022-01463-2. Cardiovasc Diabetol. 2022. PMID: 35219331 Free PMC article. Clinical Trial.
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial.
Jensen J, Omar M, Ali M, Frederiksen PH, Kistorp C, Tuxen C, Andersen CF, Larsen JH, Ersbøll MK, Køber L, Gustafsson F, Faber J, Forman JL, Møller JE, Schou M. Jensen J, et al. Among authors: tuxen c. Am Heart J. 2022 Aug;250:57-65. doi: 10.1016/j.ahj.2022.04.008. Epub 2022 May 2. Am Heart J. 2022. PMID: 35513022 Free article. Clinical Trial.
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Faber J, Fosbøl EL, Bruun NE, Brønd JC, Forman JL, Videbæk L, Møller JE, Schou M. Jensen J, et al. Among authors: tuxen c. Am Heart J. 2020 Oct;228:47-56. doi: 10.1016/j.ahj.2020.07.011. Epub 2020 Jul 17. Am Heart J. 2020. PMID: 32798787 Free article. Clinical Trial.
88 results